Osimertinib-chemotherapy synergy in EGFR-mutant NSCLC: Advancing central nervous system control amidst toxicity considerations Editorial

   

Authors:	Kumar, R.; Miao, E.; Pike, L. R. G.
Title:	Osimertinib-chemotherapy synergy in EGFR-mutant NSCLC: Advancing central nervous system control amidst toxicity considerations
Keywords:	cancer chemotherapy; cancer survival; gene mutation; overall survival; drug potentiation; monotherapy; systemic therapy; note; antineoplastic agent; progression free survival; quality of life; morbidity; epidermal growth factor receptor; local therapy; cancer mortality; blood brain barrier; stereotactic radiosurgery; cancer control; combination therapy; adverse drug reaction; non small cell lung cancer; central nervous system metastasis; randomized controlled trial (topic); whole brain radiotherapy; phase 3 clinical trial (topic); brain tissue; patient-reported outcome; cancer prognosis; combination drug therapy; disease burden; human; symptom assessment; osimertinib; european organization for research and treatment of cancer quality of life questionnaire core 30; brain metastases (bms); central nervous system efficacy (cns efficacy); epidermal growth factor receptor-mutated non-small cell lung cancer (egfr-mutated nsclc)
Journal Title:	Translational Cancer Research
Volume:	14
Issue:	4
ISSN:	2218-676X
Publisher:	Pioneer Bioscience Publishing Company
Date Published:	2025-04-30
Start Page:	2188
End Page:	2191
Language:	English
DOI:	10.21037/tcr-2024-2207
PROVIDER:	scopus
PMCID:	PMC12079210
PUBMED:	40386260
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105003939045&doi=10.21037%2ftcr-2024-2207&partnerID=40&md5=0de75d345832104bea49703c522a1639
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225603